Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

Lynlee Brown discusses the decisions that companies must make to adjust to the tariffs while also ensuring the ongoing innovation continues.

Where AI and brand translation comes in is the ability of AI to translate across disciplines. Administrative overhead increases on the amount of resources it takes to run any sort of organization. You ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and ...

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...